Entero Therapeutics, Inc.

NasdaqCM:ENTO Stock Report

Market Cap: US$2.2m

Entero Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Entero Therapeutics has a total shareholder equity of $70.8M and total debt of $177.6K, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are $86.3M and $15.5M respectively.

Key information

0.3%

Debt to equity ratio

US$177.56k

Debt

Interest coverage ration/a
CashUS$662.48k
EquityUS$70.80m
Total liabilitiesUS$15.49m
Total assetsUS$86.29m

Recent financial health updates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

Jun 07

AzurRx BioPharma: An Assessment

May 02

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

Jan 31

Financial Position Analysis

Short Term Liabilities: ENTO's short term assets ($84.4M) exceed its short term liabilities ($15.4M).

Long Term Liabilities: ENTO's short term assets ($84.4M) exceed its long term liabilities ($101.0K).


Debt to Equity History and Analysis

Debt Level: ENTO has more cash than its total debt.

Reducing Debt: ENTO's debt to equity ratio has reduced from 64.5% to 0.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENTO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ENTO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.1% each year


Discover healthy companies